Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

40.0%

2 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
P 1 (4)
P 2 (1)

Trial Status

Recruiting3
Terminated2

Clinical Trials (5)

Showing 5 of 5 trials
NCT06287463Phase 1Terminated

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

NCT06961565Phase 1RecruitingPrimary

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

NCT06299839Phase 1Recruiting

PAS-004 in Patients With Advanced Solid Tumors

NCT05735717Phase 2Recruiting

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05831995Phase 1Terminated

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Showing all 5 trials

Research Network

Activity Timeline